Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities

Cardiology Research and Practice

Volumn 1, Issue 1, 2010, Pages

  Al Mallah, Mouaz ^a   Sinno, Mohamad C N ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; AVASIMIBE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COLESTIPOL; ENALAPRIL; EPLERENONE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; NICARDIPINE; NICOTINIC ACID; NIFEDIPINE; OLMESARTAN; PACTIMIBE; PLACEBO; PRAVASTATIN; QUINAPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; STATIN; UNINDEXED DRUG;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIAC IMAGING; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 79959413254     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.4061/2010/134564     Document Type: Review

References (69)

1. Wittes J., Lakatos E., Prostfield J., Surrogate endpoints in clinical trials: cardiovascular diseases Statistics in Medicine 1989 8 4 415 425 (Pubitemid 19105889)
2. Loscalzo J., Clinical trials in cardiovascular medicine in an era of marginal benefit, bias, and hyperbole Circulation 2005 112 20 3026 3029 (Pubitemid 43113430)
3. Bse D., von Birgelen C., Erbel R., Intravascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis Journal of the American College of Cardiology 2007 49 9 925 932
4. Waters D., Craven T. E., Lesperance J., Prognostic significance of progression of coronary atherosclerosis Circulation 1993 87 4 1067 1075 (Pubitemid 23110377)
5. Willis A. L., Nagel B., Churchill V., Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits Arteriosclerosis 1985 5 3 250 255 (Pubitemid 15098000)
6. Waters D., Lesperance J., Francetich M., Causey D., Theroux P., Chiang Y.-K., Hudon G., Lemarbre L., Reitman M., Joyal M., Gosselin G., Dyrda I., Macer J., Havel R. J., A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis Circulation 1990 82 6 1940 1953
7. Borhani N. O., MIDAS: rationale, design and descriptive data of trial patients. The MIDAS Research Group Blood Pressure, Supplement 1994 3 1 29 35 (Pubitemid 24088343)
8. Borhani N. O., Brugger S. B., Byington R. P., Multicenter study with isradipine and diuretics against atherosclerosis. US MIDAS Research Group Journal of Cardiovascular Pharmacology 1990 15 supplement 1 S23 S29
9. Mancini G. B. J., Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT Canadian Journal of Cardiology 2000 16 supplement D 5D 7D
10. Zanchetti A., Agabiti Rosei E., Dal Pal C., Leonetti G., Magnani B., Pessina A., The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness Journal of Hypertension 1998 16 11 1667 1676 (Pubitemid 28515494)
11. Zannad F., Effects of calcium antagonists on the progression of atherosclerosis and intima media thickness Drugs 2000 59 2 39 46
12. Thaulow E., Jrgensen B., Results and clinical implications of the CAPARES trial Canadian Journal of Cardiology 2000 16 supplement D 8D 11D
13. Brener S. J., Ivanc T. B., Poliszczuk R., Chen M., Tuzcu E. M., Hu T., Frid D. J., Nissen S. E., Antihypertensive therapy and regression of coronary artery disease: insights from the comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials American Heart Journal 2006 152 6 1059 1063 (Pubitemid 44856714)
14. Nissen S. E., Tuzcu E. M., Schoenhagen P., Brown B. G., Ganz P., Vogel R. A., Crowe T., Howard G., Cooper C. J., Brodie B., Grines C. L., DeMaria A. N., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial Journal of the American Medical Association 2004 291 9 1071 1080 (Pubitemid 38541684)
15. MacMahon S., Sharpe N., Gamble G., Clague A., Ni Mhurchu C., Clark T., Hart H., Scott J., White H., Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial diseasepart-2: Collaborative Research Group. Prevention of Atherosclerosis with Ramipril Journal of the American College of Cardiology 2000 36 2 438 443 (Pubitemid 30624005)
16. Lonn E. M., Yusuf S., Dzavik V., Doris C. I., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W. A., Teo K. K., Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) Circulation 2001 103 7 919 925 (Pubitemid 32183795)
17. Cashin-Hemphill L., Holmvang G., Chan R. C., Pitt B., Dinsmore R. E., Lees R. S., Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators American Journal of Cardiology 1999 83 1 43 47 (Pubitemid 29036645)
18. Teo K. K., Burton J. R., Buller C. E., Plante S., Catellier D., Tymchak W., Dzavik V., Taylor D., Yokoyama S., Montague T. J., Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 2000 102 15 1748 1754
19. Takai S., Miyazaki M., Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence American Journal of Cardiovascular Drugs 2006 6 6 363 366 (Pubitemid 46072391)
20. Stumpe K. O., Agabiti-Rosei E., Zielinski T., Schremmer D., Scholze J., Laeis P., Schwandt P., Ludwig M., Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study Therapeutic Advances in Cardiovascular Disease 2007 1 2 97 106
21. Waseda K., Ozaki Y., Takashima H., Ako J., Yasukawa T., Ismail T. F., Hishida H., Ito T., Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosisan intravascular ultrasound study Circulation Journal 2006 70 9 1111 1115 (Pubitemid 44386988)
22. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results Journal of the American Medical Association 1982 247 12 1707 1714
23. Olsson G., Rehnqvist N., Sjogren A., Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity Journal of the American College of Cardiology 1985 5 6 1428 1437 (Pubitemid 15069520)
24. Julian D. G., Jackson F. S., Szekely P., Prescott R. J., A controlled trial of sotalol for 1 year after myocardial infarction Circulation 1983 67 6, part 2 I-61 I-62
25. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction New England Journal of Medicine 1981 304 14 801 807
26. Sipahi I., Tuzcu E. M., Wolski K. E., Nicholls S. J., Schoenhagen P., Hu B., Balog C., Shishehbor M., Magyar W. A., Crowe T. D., Kapadia S., Nissen S. E., -blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials Annals of Internal Medicine 2007 147 1 10 18 (Pubitemid 351664629)
27. Nissen S. E., Tuzcu E. M., Brewer H. B., Sipahi I., Nicholls S. J., Ganz P., Schoenhagen P., Waters D. D., Pepine C. J., Crowe T. D., Davidson M. H., Deanfield J. E., Wisniewski L. M., Hanyok J. J., Kassalow L. M., Effect of ACAT inhibition on the progression of coronary atherosclerosis New England Journal of Medicine 2006 354 12 1253 1263
28. Nissen S. E., Nicholls S. J., Sipahi I., Libby P., Raichlen J. S., Ballantyne C. M., Davignon J., Erbel R., Fruchart J. C., Tardif J.-C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E. M., Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial Journal of the American Medical Association 2006 295 13 1556 1565
29. Nissen S. E., Tuzcu E. M., Libby P., Thompson P. D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., Topol E. J., Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial Journal of the American Medical Association 2004 292 18 2217 2226 (Pubitemid 39473159)
30. Stier C. T. Jr., Chander P. N., Rocha R., Aldosterone as a mediator in cardiovascular injury Cardiology in Review 2002 10 2 97 107 (Pubitemid 34246658)
31. Duprez D., De Buyzere M., Rietzschel E. R., Clement D. L., Aldosterone and vascular damage Current Hypertension Reports 2000 2 3 327 334
32. Takai S., Jin D., Muramatsu M., Kirimura K., Sakonjo H., Miyazaki M., Eplerenone inhibits atherosclerosis in nonhuman primates Hypertension 2005 46 5 1135 1139 (Pubitemid 41533016)
33. Von Birgelen C., Hartmann M., Mintz G. S., Baumgart D., Schmermund A., Erbel R., Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (≥12 months) follow-up intravascular ultrasound Circulation 2003 108 22 2757 2762 (Pubitemid 37498977)
34. Azen S. P., Mack W. J., Cashin-Hemphill L., LaBree L., Shircore A. M., Selzer R. H., Blankenhorn D. H., Hodis H. N., Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the cholesterol lowering atherosclerosis study Circulation 1996 93 1 34 41 (Pubitemid 26006565)
35. Brown B. G., Zhao X.-Q., Chait A., Fisher L. D., Cheung M. C., Morse J. S., Dowdy A. A., Marino E. K., Bolson E. L., Alaupovic P., Frohlich J., Serafini L., Huss-Frechette E., Wang S., DeAngelis D., Dodek A., Albers J. J., Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease New England Journal of Medicine 2001 345 22 1583 1592 (Pubitemid 33126837)
36. Okazaki S., Yokoyama T., Miyauchi K., Shimada K., Kurata T., Sato H., Daida H., Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study Circulation 2004 110 9 1061 1068 (Pubitemid 39319003)
37. Matsuzaki M., Hiramori K., Imaizumi T., Kitabatake A., Hishida H., Nomura M., Fuj T. II, Sakuma I., Fukami K., Honda T., Ogawa H., Yamagishi M., Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART) Journal of the American College of Cardiology 2002 40 2 220 227 (Pubitemid 34756279)
38. Ballantyne C. M., Raichlen J. S., Nicholls S. J., Erbel R., Tardif J.-C., Brener S. J., Cain V. A., Nissen S. E., Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 2008 117 19 2458 2466 (Pubitemid 351670452)
39. Schartl M., Bocksch W., Koschyk D. H., Voelker W., Karsch K. R., Kreuzer J., Hausmann D., Beckmann S., Gross M., Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease Circulation 2001 104 4 387 392 (Pubitemid 32678266)
40. Kastelein J. J. P., Akdim F., Stroes E. S. G., Zwinderman A. H., Bots M. L., Stalenhoef A. F. H., Visseren F. L. J., Sijbrands E. J. G., Trip M. D., Stein E. A., Gaudet D., Duivenvoorden R., Veltri E. P., Marais A. D., De Groot E., Simvastatin with or without ezetimibe in familial hypercholesterolemia New England Journal of Medicine 2008 358 14 1431 1443 (Pubitemid 351482735)
41. Fleg J. L., Mete M., Howard B. V., Umans J. G., Roman M. J., Ratner R. E., Silverman A., Galloway J. M., Henderson J. A., Weir M. R., Wilson C., Stylianou M., Howard WM. J., Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial Journal of the American College of Cardiology 2008 52 25 2198 2205
42. Crouse J. R. III, Grobbee D. E., O'Leary D. H., Bots M. L., Evans G. W., Palmer M. K., Riley W. A., Raichlen J. S., Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosisthe rationale and methodology of the METEOR study Cardiovascular Drugs and Therapy 2004 18 3 231 238 (Pubitemid 38918958)
43. Taylor A. J., Villines T. C., Stanek E. J., Devine P. J., Griffen L., Miller M., Weissman N. J., Turco M., Extended-release niacin or ezetimibe and carotid intima-media thickness New England Journal of Medicine 2009 361 22 2113 2122
44. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 2001 357 9260 905 910
45. Hiukka A., Westerbacka J., Leinonen E. S., Watanabe H., Wiklund O., Hulten L. M., Salonen J. T., Tuomainen T.-P., Yki-Jrvinen H., Keech A. C., Taskinen M.-R., Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus Journal of the American College of Cardiology 2008 52 25 2190 2197
46. Zhu S., Su G., Meng Q. H., Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension Clinical Chemistry 2006 52 11 2036 2042 (Pubitemid 44658204)
47. Elkeles R. S., Diamond J. R., Poulter C., Dhanjil S., Nicolaides A. N., Mahmood S., Richmond W., Mather H., Sharp P., Feher M. D., Cardiovascular outcomes in type 2 diabetes: a double-blind placebo- controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Diabetes Care 1998 21 4 641 648 (Pubitemid 28172949)
48. Nicholls S. J., Sipahi I., Schoenhagen P., Wisniewski L., Churchill T., Crowe T., Goormastic M., Wolski K., Tuzcu E. M., Nissen S. E., Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study American Heart Journal 2006 152 1 67 74 (Pubitemid 43974735)
49. Tardif J.-C., Grégoire J., Lespérance J., Lambert J., L'Allier P. L., Rodés J., Anderson T., Blue J. W., Imus J., Heinonen T., Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial American Heart Journal 2002 144 4 589 596
50. Tardif J.-C., Grégoire J., L'Allier P. L., Anderson T. J., Bertrand O., Reeves F., Title L. M., Alfonso F., Schampaert E., Hassan A., McLain R., Pressler M. L., Ibrahim R., Lespérance J., Blue J., Heinonen T., Rodés-Cabau J., Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions Circulation 2004 110 21 3372 3377 (Pubitemid 39557502)
51. Ameli S., Hultgardh-Nilsson A., Cercek B., Shah P. K., Forrester J. S., Ageland H., Nilsson J., Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 1994 90 4 1935 1941 (Pubitemid 24320945)
52. Nissen S. E., Tsunoda T., Tuzcu E. M., Schoenhagen P., Cooper C. J., Yasin M., Eaton G. M., Lauer M. A., Sheldon W. S., Grines C. L., Halpern S., Crowe T., Blankenship J. C., Kerensky R., Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial Journal of the American Medical Association 2003 290 17 2292 2300 (Pubitemid 37430562)
53. Davies M. J., Richardson P. D., Woolf N., Katz D. R., Mann J., Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content British Heart Journal 1993 69 5 377 381 (Pubitemid 23171108)
54. Leitinger N., Watson A. D., Hama S. Y., Ivandic B., Qiao J.-H., Huber J., Faull K. F., Grass D. S., Navab M., Fogelman A. M., De Beer F. C., Lusis A. J., Berliner J. A., Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 5 1291 1298 (Pubitemid 29227650)
55. Packard C. J., O'Reilly D. S. J., Caslake M. J., McMahon A. D., Ford I., Cooney J., MacPhee C. H., Suckling K. E., Krishna M., Wilkinson F. E., Rumley A., Lowe G. D.O., Docherty G., Burczak J. D., Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group New England Journal of Medicine 2000 343 16 1148 1155
56. Hodis H. N., Mack W. J., LaBree L., Mahrer P. R., Sevanian A., Liu C.-R., Liu C.-H., Hwang J., Selzer R. H., Azen S. P., Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS) Circulation 2002 106 12 1453 1459
57. Salonen R. M., Nyyssnen K., Kaikkonen J., Porkkala-Sarataho E., Voutilainen S., Rissanen T. H., Tuomainen T.-P., Valkonen V.-P., Ristonmaa U., Lakka H.-M., Vanharanta M., Salonen J. T., Poulsen H. E., Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study Circulation 2003 107 7 947 953 (Pubitemid 36258715)
58. Behrendt D., Beltrame J., Hikiti H., Wainstein M., Kinlay S., Selwyn A. P., Ganz P., Fang J. C., Impact of coronary endothelial function on the progression of cardiac transplant-associated arteriosclerosis: effect of anti-oxidant vitamins C and E Journal of Heart and Lung Transplantation 2006 25 4 426 433
59. Fang J. C., Kinlay S., Beltrame J., Hikiti H., Wainstein M., Behrendt D., Suh J., Frei B., Mudge G. H., Selwyn A. P., Ganz P., Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial Lancet 2002 359 9312 1108 1113 (Pubitemid 34270735)
60. Nunes G. L., Abizaid A. C., Theodoro M. P., Brito F. S. Jr., Caixeta A., da Silva L. F. F., Mazzotti N. G., Bell-Klein A., Clausell N., Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study American Heart Journal 2006 152 5 914.e1 914.e7
61. Tardif J.-C., Grégoire J., Schwartz L., Title L., Laramée L., Reeves F., Lespérance J., Bourassa M. G., L'Allier P. L., Glass M., Lambert J., Guertin M.-C., Effects of AGI-1067 and probucol after percutaneous coronary interventions Circulation 2003 107 4 552 558 (Pubitemid 36176803)
62. Tardif J.-C., Grégoire J., L'Allier P. L., Ibrahim R., Anderson T. J., Reeves F., Title L. M., Schampaert E., LeMay M., Lespérance J., Scott R., Guertin M.-C., Brennan M.-L., Hazen S. L., Bertrand O. F., Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial Atherosclerosis 2008 197 1 480 486 (Pubitemid 351273228)
63. Després J.-P., Golay A., Sjstrm L., Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia New England Journal of Medicine 2005 353 20 2121 2134 (Pubitemid 41653104)
64. Pi-Sunyer F. X., Aronne L. J., Heshmati H. M., Devin J., Rosenstock J., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patientsRIO-North America: a randomized controlled trial Journal of the American Medical Association 2006 295 7 761 775 (Pubitemid 43244304)
65. Scheen A. J., Cannabinoid-1 receptor antagonists in type-2 diabetes Best Practice and Research: Clinical Endocrinology and Metabolism 2007 21 4 535 553 (Pubitemid 350182234)
66. Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rssner S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 2005 365 9468 1389 1397 (Pubitemid 40523733)
67. Nissen S. E., Nicholls S. J., Wolski K., Rodés-Cabau J., Cannon C. P., Deanfield J. E., Després J.-P., Kastelein J. J. P., Steinhubl S. R., Kapadia S., Yasin M., Ruzyllo W., Gaudin C., Job B., Hu B., Bhatt D. L., Lincoff A. M., Tuzcu E. M., Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial Journal of the American Medical Association 2008 299 13 1547 1560 (Pubitemid 351482794)
68. Nissen S. E., Nicholls S. J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochellire R., Staniloae C. S., Mavromatis K., Saw J., Hu B., Lincoff A. M., Tuzcu E. M., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial Journal of the American Medical Association 2008 299 13 1561 1573 (Pubitemid 351482795)
69. Mazzone T., Meyer P. M., Feinstein S. B., Davidson M. H., Kondos G. T., D'Agostino R. B. Sr., Perez A., Provost J.-C., Haffner S. M., Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial Journal of the American Medical Association 2006 296 21 2572 2581 (Pubitemid 44903861)